EUROFINS SCIENTIFIC : Eurofins expands its genomic activities

le
0

November 22, 2007

This week, three companies offering genomic services (e.g. custom production of synthetic nucleic acid, DNA analysis, proteomic services) in Germany, Japan and the USA have joined the Eurofins Group. With about 200 employees these companies achieved a turnover of over ¤ 20 million in 2006 and should contribute positively to the result of the Eurofins Group from 2008 onwards.

A number of molecular biology methods have been developed over the past 25 years based on the availability and affordability of custom synthetic nucleic acids such as DNA-amplification, DNA-sequencing, SNP-analysis, gene synthesis and genotyping. Custom sequences of synthetic nucleic acid can now be produced within 24 hours and are used for the analysis of genetic fragments derived from natural samples in order to analyse their structure and potential mutation. These molecular biology methods have a growing usage in many sectors of the industry including food and feed safety, environmental control, pharmaceutical drug and diagnostic development. They are also one of the main tools currently used in life science research.

Molecular-biological techniques are used to develop new generations of drugs in clinical research. They enable optimisation of the research by taking into consideration genetic differences in individuals, improving effectiveness and reducing side effects. Synthetic nucleine acids are futher utilised in clinical diagnostics and also the agricultural industry to discover metastases, viral infections and contamination of food. “Through these acquisitions we will, together with our new partners, improve our market penetration in the area of molecular-biological research”, said Dr. Gilles Martin, CEO of Eurofins.

For further information about Eurofins please visit www.eurofins.com or contact: Investor Relations Phone: +32-2-769 7383 E-mail: ir@eurofins.com

Notes for the editor: Eurofins - a global leader in bio-analysis Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With over 7,000 staff in more than 100 laboratories across 27 countries, Eurofins offers a portfolio of over 25,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to provide its customers with high quality services, accurate results in time and, if requested, expert advice by our highly qualified staff. The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both, its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international player in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the demands of regulatory authorities around the world. The shares of Eurofins Scientific are listed on Euronext in the Paris (ISIN FR0000038259) and Frankfurt (WKN 910251) Stock Exchanges (Reuters EUFI.LN, Bloomberg ERF FP, ESF, EUFI.DE).

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.

© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free

Valeur associée
  Libellé Bourse Dernier Var. Vol.
Vous devez être membre pour ajouter des commentaires.
Devenez membre, ou connectez-vous.
Aucun commentaire n'est disponible pour l'instant